Company news
Glucotrack, Inc. (NASDAQ:GCTK) news
Glucotrack, Inc. news releases on 6ix. Latest, Sep 24, 2026: Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
Press releases & updates
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
September 24, 2026
Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
September 23, 2026
Glucotrack Announces $11.5 Million Financing
September 11, 2026
Glucotrack, Inc. Announces Reverse Stock Split
August 27, 2026
Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation
August 17, 2026
E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack
August 6, 2026
Glucotrack Announces $5.5 Million Financing
August 5, 2026
Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline
July 31, 2026
Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
July 29, 2026
E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing
July 17, 2026
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
July 17, 2026
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
July 16, 2026
Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
July 14, 2026
Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
July 8, 2026
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions
May 26, 2026
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
May 7, 2026
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
April 30, 2026
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
April 21, 2026
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 29, 2026
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
March 26, 2026
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
March 9, 2026
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
January 29, 2026
Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
December 30, 2025
Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights
November 13, 2025
Glucotrack, Inc. Encourages Shareholders to Vote
November 3, 2025
Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team
October 29, 2025
Glucotrack, Inc. Reminds Shareholders to Vote
October 28, 2025
Glucotrack to Participate in the Q3 Virtual Investor Summit
September 11, 2025
Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 14, 2025
Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology
August 6, 2025
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting
July 31, 2025
Glucotrack Announces Repurchase of Series A Warrants
July 8, 2025
Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
June 25, 2025
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
June 12, 2025
Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes Management
June 9, 2025
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
June 4, 2025
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives
May 28, 2025
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
May 28, 2025
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
May 20, 2025
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 14, 2025
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes Patients
May 13, 2025
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
May 13, 2025
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
April 16, 2025
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
April 3, 2025
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
March 31, 2025
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
March 19, 2025
Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes Care
March 18, 2025
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
February 26, 2025
Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial
February 24, 2025